ESR2 and prostate carcinoma: In addition, the remaining altered genes that are not depicted in the KEGG Pathway schematic, including ESR2 (−5.26, p = 0.013) and CDH1 (−2.08, p = 0.019), are implicated in prostate cancer progression [42, 43].